NEW YORK (GenomeWeb News) – Rules-Based Medicine today said that it has acquired intellectual property assets covering biomarker technology from Satoris.
The deal includes biomarkers and biomarker panels for clinical research use for Alzheimer's disease, frontal temporal dementia, Parkinson's disease, and other central nervous system conditions.
Two years ago, Redwood City, Calif.-based Satoris had signed an agreement to distribute RBM's DiscoveryMAP panel for neurology research. It also sells its own Dementia Discrimination panel, which it said is used to differentiate Alzheimer's patients from patients with other forms of dementia.
"These assets from Satoris will be an important contributor as we continue to develop research and diagnostic offerings for neurodegenerative illnesses which affect millions of individuals and families," Craig Benson, president and CEO of Rules-Based Medicine, said in a statement.
Financial terms of the agreement were not disclosed.
Austin, Texas-based RBM agreed last month to be acquired by Myriad Genetics for $80 million.